艾迪注射液联合GP方案在晚期非小细胞肺癌中的应用效果

Application effect of Aidi injection combined with GP scheme in advanced non-small cell lung cancer

目的探究艾迪注射液联合GP方案在晚期非小细胞肺癌(NSCLC)的应用效果。方法选取2016年7月至2018年6月我院收治的86例晚期NSCLC患者作为研究对象,按随机数字表法将其分为对照组和观察组,各43例。对照组采用常规GP化疗方案,观察组采用艾迪注射液联合GP化疗方案,比较两组患者的近期疗效、免疫功能指标和远期疗效。结果观察组近期治疗总有效率高于对照组(P<0.05)。化疗前,两组患者免疫功能指标水平比较,差异无统计学意义(P>0.05)。化疗后,两组患者CD3^+、CD4^+水平及CD4^+/CD8^+均低于化疗前,CD8^+水平高于化疗前,观察组CD3^+、CD4^+水平及CD4^+/CD8^+高于对照组,CD8^+水平低于对照组(P<0.05)。观察组患者平均中位生存期和平均无进展生存期均长于对照组(P<0.05)。结论艾迪注射液联合GP化疗方案在晚期NSCLC的化疗中近期疗效显著,可增强患者机体的免疫功能,延长患者生存期。

Objective To explore the application effect of Aidi injection combined with GP scheme in advanced non-small cell lung cancer (NSCLC). Methods Eighty-six patients with advanced NSCLC in our hospital from July 2016 to June 2018 were selected as the study objects, and divided into control group and observation group according to the random number table method, with 43 cases in each group. The control group was treated with conventional GP chemotherapy, while the observation group was treated with Aidi injection combined with GP chemotherapy. The short-term effects, immune function indexes and long-term effects of the two groups were compared. Results The total effective rate of short-term treatment in the observation group was higher than that in the control group (P<0.05). Before chemotherapy, there were no significant differences in the levels of immune function indexes between the two groups (P>0.05). After chemotherapy, the levels of CD3^+, CD4^+ and CD4^+/CD8^+ in the two groups were lower than those before chemotherapy, and the levels of CD8^+ was higher than those before chemotherapy, the levels of CD3^+, CD4^+ and CD4^+/CD8^+ in the observation group were higher than those in the control group, and the level of CD8+ in the observation group was lower than that in the control group (P<0.05). The average median survival time and average progression-free survival time of patients in the observation group were longer than those in the control group (P<0.05). Conclusion Aidi injection combined with GP chemotherapy in advanced NSCLC has a significant short-term effect, it can enhance the immune function of patients, and can prolonged survival time.